Literature DB >> 25559596

No relationship between drug transporter genetic variants and tenofovir plasma concentrations or changes in glomerular filtration rate in HIV-infected adults.

Wasna Sirirungsi1, Saik Urien, Linda Harrison, Jiraporn Kamkon, Yardpiroon Tawon, Nuananong Luekamlung, Suchart Thongpaen, Ampaipith Nilmanat, Gonzague Jourdain, Marc Lallemant, Sophie Le Coeur, Nicole Ngo-Giang-Huong, Andrew Owen, Tim R Cressey.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25559596      PMCID： PMC4334716          DOI： 10.1097/QAI.0000000000000504

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN： 1525-4135            Impact factor:   3.731


× No keyword cloud information.
  11 in total

1.  Incidence and risk factors for tenofovir-associated renal function decline among Thai HIV-infected patients with low-body weight.

Authors:  Kessarin Chaisiri; Chureeratana Bowonwatanuwong; Narat Kasettratat; Sasisopin Kiertiburanakul
Journal:  Curr HIV Res       Date:  2010-10       Impact factor: 1.581

Review 2.  Antiretrovirals and the kidney in current clinical practice: renal pharmacokinetics, alterations of renal function and renal toxicity.

Authors:  Jean C Yombi; Anton Pozniak; Marta Boffito; Rachael Jones; Saye Khoo; Jeremy Levy; Frank A Post
Journal:  AIDS       Date:  2014-03-13       Impact factor: 4.177

3.  Estimation of population pharmacokinetic parameters of saquinavir in HIV patients with the MONOLIX software.

Authors:  Marc Lavielle; France Mentré
Journal:  J Pharmacokinet Pharmacodyn       Date:  2007-01-09       Impact factor: 2.745

4.  Pregnancy-related effects on tenofovir pharmacokinetics: a population study with 186 women.

Authors:  Sihem Benaboud; Déborah Hirt; Odile Launay; Emmanuelle Pannier; Ghislaine Firtion; Elisabeth Rey; Naïm Bouazza; Frantz Foissac; Hélène Chappuy; Saik Urien; Jean Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-11-28       Impact factor: 5.191

5.  Pharmacokinetic study of tenofovir disoproxil fumarate combined with rifampin in healthy volunteers.

Authors:  J A H Droste; C P W G M Verweij-van Wissen; B P Kearney; R Buffels; P J Vanhorssen; Y A Hekster; D M Burger
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

6.  Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.

Authors:  Sonia Rodríguez-Nóvoa; Pablo Labarga; Vincent Soriano; Deirdre Egan; Marta Albalater; Judit Morello; Lorena Cuenca; Gema González-Pardo; Saye Khoo; David Back; Andrew Owen
Journal:  Clin Infect Dis       Date:  2009-06-01       Impact factor: 9.079

Review 7.  Pharmacogenetics of tenofovir treatment.

Authors:  Sonia Rodriguez-Novoa; Pablo Labarga; Vincent Soriano
Journal:  Pharmacogenomics       Date:  2009-10       Impact factor: 2.533

8.  The effect of lopinavir/ritonavir on the renal clearance of tenofovir in HIV-infected patients.

Authors:  J J Kiser; M L Carten; C L Aquilante; P L Anderson; P Wolfe; T M King; T Delahunty; L R Bushman; C V Fletcher
Journal:  Clin Pharmacol Ther       Date:  2007-06-27       Impact factor: 6.875

9.  Renal impairment in patients receiving a tenofovir-cART regimen: impact of tenofovir trough concentration.

Authors:  Isabelle Poizot-Martin; Caroline Solas; Julie Allemand; Véronique Obry-Roguet; Vincent Pradel; Sylvie Bregigeon; Olivia Faucher; Bruno Lacarelle
Journal:  J Acquir Immune Defic Syndr       Date:  2013-04-01       Impact factor: 3.731

10.  Impact of small body weight on tenofovir-associated renal dysfunction in HIV-infected patients: a retrospective cohort study of Japanese patients.

Authors:  Takeshi Nishijima; Hirokazu Komatsu; Hiroyuki Gatanaga; Takahiro Aoki; Koji Watanabe; Ei Kinai; Haruhito Honda; Junko Tanuma; Hirohisa Yazaki; Kunihisa Tsukada; Miwako Honda; Katsuji Teruya; Yoshimi Kikuchi; Shinichi Oka
Journal:  PLoS One       Date:  2011-07-25       Impact factor: 3.240
View more
  5 in total

1.  Plasma pharmacokinetics and urinary excretion of tenofovir following cessation in adults with controlled levels of adherence to tenofovir disoproxil fumarate.

Authors:  Tim R Cressey; Oraphan Siriprakaisil; Rachel W Kubiak; Virat Klinbuayaem; Pra-Ornsuda Sukrakanchana; Justice Quame-Amaglo; Hideaki Okochi; Yardpiroon Tawon; Ratchada Cressey; Jared M Baeten; Monica Gandhi; Paul K Drain
Journal:  Int J Infect Dis       Date:  2020-06-14       Impact factor: 3.623

2.  Plasma and Intracellular Pharmacokinetics of Tenofovir Disoproxil Fumarate 300 mg Every 48 Hours vs 150 mg Once Daily in HIV-Infected Adults With Moderate Renal Function Impairment.

Authors:  Tim R Cressey; Anchalee Avihingsanon; Guttiga Halue; Prattana Leenasirimakul; Pra-Ornsuda Sukrakanchana; Yardpiroon Tawon; Nirattiya Jaisieng; Gonzague Jourdain; Anthony T Podany; Courtney V Fletcher; Virat Klinbuayaem; Chureeratana Bowonwatanuwong
Journal:  Clin Infect Dis       Date:  2015-04-28       Impact factor: 9.079

3.  Tenofovir Exposure during Pregnancy and Postpartum in Women Receiving Tenofovir Disoproxil Fumarate for the Prevention of Mother-to-Child Transmission of Hepatitis B Virus.

Authors:  Tim R Cressey; Linda Harrison; Jullapong Achalapong; Prateep Kanjanavikai; Orada Patamasingh Na Ayudhaya; Prateung Liampongsabuddhi; Thitiporn Siriwachirachai; Chaiwat Putiyanun; Pornnapa Suriyachai; Camlin Tierney; Nicolas Salvadori; Dujrudee Chinwong; Luc Decker; Yardpiroon Tawon; Trudy V Murphy; Nicole Ngo-Giang-Huong; George K Siberry; Gonzague Jourdain
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

4.  Drug Transporter Genetic Variants Are Not Associated with TDF-Related Renal Dysfunction in Patients with HIV-1 Infection: A Pharmacogenetic Study.

Authors:  Takeshi Nishijima; Tsunefusa Hayashida; Takuma Kurosawa; Noriko Tanaka; Shinichi Oka; Hiroyuki Gatanaga
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

5.  Effect of Pregnancy and Concomitant Antiretrovirals on the Pharmacokinetics of Tenofovir in Women With HIV Receiving Tenofovir Disoproxil Fumarate-Based Antiretroviral Therapy Versus Women With HBV Receiving Tenofovir Disoproxil Fumarate Monotherapy.

Authors:  Vera E Bukkems; Elise J Smolders; Gonzague Jourdain; David M Burger; Angela P Colbers; Tim R Cressey
Journal:  J Clin Pharmacol       Date:  2020-09-22       Impact factor: 3.126
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.